Literature DB >> 21503398

Chlamydia trachomatis and human papillomavirus coinfection: association with p16INK4a and Ki67 expression in biopsies of patients with pre-neoplastic and neoplastic lesions.

Luciane Noal Calil1, Cristine Nascente Igansi, Luise Meurer, Maria Isabel Albano Edelweiss, Mary Clarisse Bozzetti.   

Abstract

The objective of this study was to identify the frequency of coinfection by human papillomavirus (HPV) and Chlamydia trachomatis (CT) in cervical lesions and relate it with immunohistochemical expression of p16INK4a and Ki67, both oncogenicity markers. A cross-sectional study with 86 women from primary care units in southern Brazil was conducted. Cervical swabs were collected for HPV-DNA and CT-DNA detection, through the polymerase chain reaction technique (PCR). The immunohistochemical analysis was performed on biopsy cervical tissue material to identify the expression of p16INK4a and Ki67 cell cycle markers. About 83 % were positive for HPV-DNA and 19% had coinfection with CT-DNA. Among coinfected women, 56% expressed p16INK4a. There was a statistically significant association between the histological grade of the lesion and Ki67 expression. All high-grade lesions, 50% of low-grade lesions and 31% of negative biopsies expressed Ki67 (p = 0.004). A total of 37% of coinfected women expressed both markers. In conclusion, although more than half of the coinfected patients have expressed p16INK4a and more than one third have expressed both markers, these results suggest no association between those variables. However, other studies involving larger samples are necessary to corroborate such findings.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21503398     DOI: 10.1016/s1413-8670(11)70157-x

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  6 in total

1.  Prevalence of Chlamydia trachomatis endocervical infection in systemic lupus erythematosus patients and evaluation of the risk for HPV-induced lesions.

Authors:  Licia CostaPinto; Viviana Gallazzi Olavarria; Maria Fernanda Rios Grassi; Leomar D' Cirqueira Lyrio; Rone Peterson Cerqueira Oliveira; Iuri Usêda Santana; Cristiane Bahiana Cruz; Mittermayer Barreto Santiago
Journal:  Rheumatol Int       Date:  2012-04-07       Impact factor: 2.631

Review 2.  Chlamydia Infection as a Risk Factor for Cervical Cancer: A Systematic Review and Meta-Analysis.

Authors:  Anaanthan Bhuvanendran Pillai; Chin Mun Wong; Noor Dalila Inche Zainal Abidin; Sharifah Fazlinda Syed Nor; Mohd Fathulzhafran Mohamed Hanan; Siti Rasidah Abd Ghani; Nurul Afzan Aminuddin; Nazarudin Safian
Journal:  Iran J Public Health       Date:  2022-03       Impact factor: 1.479

3.  Molecular detection of HPV and Chlamydia trachomatis infections in Brazilian women with abnormal cervical cytology.

Authors:  André L P de Abreu; Paula R B Nogara; Raquel P Souza; Mariana C da Silva; Nelson S Uchimura; Rodrigo L Zanko; Erika C Ferreira; Maria C B Tognim; Jorge J V Teixeira; Fabrícia Gimenes; Marcia E L Consolaro
Journal:  Am J Trop Med Hyg       Date:  2012-11-05       Impact factor: 2.345

4.  Prevalence of Chlamydia trachomatis in an asymptomatic female population attending cervical cytology services of three healthcare centers in Medellín, Colombia

Authors:  Nataly Orozco-Hoyos; Armando Baena; Carolina Montoya-Ruiz; Gloria I Sánchez; Eliana Restrepo
Journal:  Biomedica       Date:  2020-09-01       Impact factor: 0.935

Review 5.  The Role of Chlamydia Trachomatis in the Pathogenesis of Cervical Cancer.

Authors:  Ana P Arcia Franchini; Beshoy Iskander; Fatima Anwer; Federico Oliveri; Kakargias Fotios; Priyanka Panday; Pousette Hamid
Journal:  Cureus       Date:  2022-01-17

6.  Chlamydia trachomatis Frequency in a Cohort of HPV-Infected Colombian Women.

Authors:  Edith Margarita Quinónez-Calvache; Dora Inés Ríos-Chaparro; Juan David Ramírez; Sara Cecilia Soto-De León; Milena Camargo; Luisa Del Río-Ospina; Ricardo Sánchez; Manuel Elkin Patarroyo; Manuel Alfonso Patarroyo
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.